Presented by Matthew F. Kalady, MD at the SAGES 2013 Annual Meeting; SAGES/ISLCRS/ASCRS Symposium – Optimizing Outcomes in Rectal Cancer
disclosures–13 sec
rectal cx tx paradigm–15 sec
rectal cx outcome paradigm–1:05
personalized medicine–1:41
challenges in rectal cx–2:12
current knowledge limitations–2:45
potential markers
Keyword(s): 5-FU metabolism, algorithm, algorithm flowchart, amino acid switch, Annals of Surgical Oncology, ASCRS, Australia, biological response, biologically heterogeneous populations, biology, biomarker profile, bx, c-K-ras gene mutations, Cancer Research, cellular proliferation, class prediction, Clinical Cancer Research, Clinical Gastroenterology & Hepatology, clinical practice, clinical staging, clinical utility, codons, colon cx, colorectal carcinogenesis, colorectal cx, combination DNA profiles, conflicting data, cross-validation, CRT, cyclin D1 G870A, DCR, decision point, differential expression, disease genetics, DNA microarray analysis, downstream effector, drug resistance, EGFR pathway, endpoint, enzyme, experimental, G12V mutation, G13D, gene banks, gene expression profiling, gene signature, gene status, gene-signature, genes, genetic markers, genetic polymorphisms, genetic profile testing, genetic profiling technology, genotype, genotype-directed neoadjuvant CRT, genteic markers, German rectal cx trial, Germany, high risk, histological response, individual markers, internal validation, International Journal of Radiation Oncology, investigation, irinotecan, ISLCRS, Japan, Journal of Clinical Oncology, KRAS mutations, KRAS oncogene, metastatic colorectal adenocarcinoma, metastatic disease, methylenetetrahydrofolate reductase, microarray gene expression profiling, microarray platforms, molecular genetic changes, molecular markers, mutation, NCCN guidelines, nCRT, neoadjuvant therapy, outcome measures, over tx, pathologic staging, pCR, personalized medicine, personalized tx, polymorphisms, predictive classifiers, predictive medicine, predictive models, predictive value, predictive values, preop XRT, preoperative chemoradiotherapy, pretx bx, pretx staging, pretx transcriptional profiling, prognostic models, prognostic values, prospective collected data, prospective phase II trial, prospective validation trials, Radiotherapy & Oncology, rectal cx, rectal cx cells, rectal cx outcome, research, response prediction, retrospective evaluation, retrospective reviews, sample classification, sample validation set, sensitivity, serum DNA, signal transduction, SNPs, South Korea, specificity, stage II tumors, stage III tumors, standard clinical applications, standard therapy, statistical analyses, study designs, surgical approach, surgical resection, T-level downsizing, thymidaylate synthase SNPs, thymidylate synthase, toxicity, TS genotype, tumor, tumor downstaging, tumor regression, tumor response, tumor-response marker, tx protocols, tyrosine kinase, under tx, validated models, whole genome analyses, ypT0